Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by Sumitomo Mitsui Trust Holdings Inc.

Sumitomo Mitsui Trust Holdings Inc. boosted its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 16.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,081,869 shares of the company's stock after buying an additional 154,112 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned approximately 0.28% of Moderna worth $107,592,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. Cim Investment Management Inc. lifted its holdings in Moderna by 4.2% in the first quarter. Cim Investment Management Inc. now owns 2,139 shares of the company's stock valued at $329,000 after acquiring an additional 86 shares during the period. Cetera Advisor Networks LLC lifted its holdings in Moderna by 0.5% in the fourth quarter. Cetera Advisor Networks LLC now owns 17,195 shares of the company's stock valued at $3,088,000 after acquiring an additional 87 shares during the period. Ancora Advisors LLC raised its stake in shares of Moderna by 41.2% during the 1st quarter. Ancora Advisors LLC now owns 329 shares of the company's stock worth $51,000 after buying an additional 96 shares during the period. Sunbelt Securities Inc. raised its stake in shares of Moderna by 7.5% during the 1st quarter. Sunbelt Securities Inc. now owns 1,428 shares of the company's stock worth $211,000 after buying an additional 100 shares during the period. Finally, Allworth Financial LP raised its stake in shares of Moderna by 6.5% during the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company's stock worth $165,000 after buying an additional 101 shares during the period. Hedge funds and other institutional investors own 75.33% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on MRNA. HSBC reaffirmed a "reduce" rating and set a $86.00 target price (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research note on Monday, April 1st. Needham & Company LLC reaffirmed a "hold" rating on shares of Moderna in a research note on Thursday, April 11th. Jefferies Financial Group reaffirmed a "buy" rating and set a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. Finally, Oppenheimer raised Moderna from a "market perform" rating to an "outperform" rating and set a $142.00 target price for the company in a research note on Tuesday, January 2nd. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $126.49.

Moderna Trading Down 0.3 %

NASDAQ:MRNA traded down $0.35 during trading hours on Wednesday, hitting $103.44. The company had a trading volume of 1,999,889 shares, compared to its average volume of 4,213,013. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. The company has a 50-day moving average of $100.10 and a 200 day moving average of $93.52. The company has a market cap of $39.61 billion, a P/E ratio of -8.34 and a beta of 1.62. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $144.93.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion during the quarter, compared to analysts' expectations of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The firm's quarterly revenue was down 44.9% on a year-over-year basis. During the same period in the prior year, the business earned $3.61 EPS. Sell-side analysts expect that Moderna, Inc. will post -7.51 earnings per share for the current year.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 647 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the transaction, the chief financial officer now directly owns 4,300 shares in the company, valued at approximately $406,651. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CFO James M. Mock sold 647 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the transaction, the chief financial officer now directly owns 4,300 shares in the company, valued at approximately $406,651. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, President Stephen Hoge sold 2,388 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $225,833.16. Following the transaction, the president now owns 1,515,898 shares of the company's stock, valued at $143,358,473.86. The disclosure for this sale can be found here. Insiders sold a total of 94,954 shares of company stock worth $9,983,276 in the last three months. 15.20% of the stock is owned by corporate insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.